The Saudi Food and Drug Authority said in a statement that its chief executive officer, Dr. Hisham S. Aljadhey, signed the memorandum of understanding with MHRA chief executive Lawrence Tallon on the sidelines of the DIA-MHRA Global Summit in London. The event ran from November 16 to 17, 2026, with MHRA chair Anthony Harnden in attendance at the signing ceremony. The authority added that the two sides then held a bilateral meeting to review cooperation priorities amid the latest scientific and regulatory advances. According to the SFDA statement, the agreement builds on prior collaboration between the regulators and reflects a joint focus on keeping pace with medical innovation.
The memorandum centers on enhancing the evaluation of treatments for rare diseases, advanced therapies and biotechnology products, the SFDA reported. It further provides for the exchange of expertise on applying artificial intelligence, modeling and computer simulation techniques within clinical studies and trials. Such cooperation offers developers clearer guidance on regulatory expectations from an early stage, particularly for therapies aimed at patients with few existing options, according to the authority’s announcement. The SFDA noted that the pact maintains stringent requirements for safety, quality and efficacy throughout accelerated review pathways.
Under the memorandum the regulators will share information and best practices on medical product registration and assessment procedures, the SFDA stated. Additional areas of cooperation include good manufacturing practices, quality management systems, laboratory testing and analysis methods, and monitoring of supply chains. These exchanges are designed to bolster the safety of medical products reaching markets in both Saudi Arabia and the United Kingdom while enabling both agencies to detect and address potential risks more effectively.
The agreement aligns with objectives in Saudi Vision 2030 that seek to raise quality of life by improving timely access to safe and effective treatments, the SFDA indicated in its release. It also supports the Kingdom’s National Biotechnology Strategy, which focuses on strengthening domestic capabilities and fostering innovation across the sector through scientific knowledge exchange and refined regulatory assessment tools. The authority highlighted that the partnership with the MHRA forms part of broader efforts to position Saudi Arabia as a hub for advanced healthcare solutions in the region.
Both organizations have maintained regular technical dialogue in recent years on harmonizing regulatory approaches to emerging therapies, according to the SFDA statement. The latest memorandum formalizes and expands that dialogue into concrete workstreams on artificial intelligence applications and specialized product categories. Officials from the two agencies anticipate that the framework will reduce duplication in reviews where appropriate while preserving independent decision-making on approvals within each jurisdiction.
Developers of novel treatments stand to benefit from earlier regulatory clarity under the new cooperation channel, the SFDA explained. The authority added that patients in Saudi Arabia and the United Kingdom could gain quicker access to therapies for conditions that previously lacked adequate options. The statement described the memorandum as a step toward more agile yet robust oversight of medical innovation across both markets.
ع